Sarepta Therapeutics
SRPT
346 hedge funds and large institutions have $2.01B invested in Sarepta Therapeutics in 2025 Q4 according to their latest regulatory filings, with 73 funds opening new positions, 136 increasing their positions, 90 reducing their positions, and 43 closing their positions.
70% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 43
51% more repeat investments, than reductions
Existing positions increased: 136 | Existing positions reduced: 90
20% more capital invested
Capital invested by funds: $1.67B → $2.01B (+$339M)
8% more funds holding
Funds holding: 320 → 346 (+26)
0.29% more ownership
Funds ownership: 88.83% → 89.12% (+0.29%)
16% less call options, than puts
Call options by funds: $114M | Put options by funds: $136M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$135M |
| 2 |
State Street
Boston,
Massachusetts
|
+$27.3M |
| 3 |
BlackRock
New York
|
+$22.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20.9M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$18.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$31.4M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$22.2M |
| 3 |
Amundi
Paris,
France
|
-$20.2M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$16M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$14M |
SRPT Hedge Fund Activity: Q4 2025 in Review
346 institutional investors reported a position in Sarepta Therapeutics (SRPT) for Q4 2025, worth a combined $2.01B — up 20% from $1.67B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new SRPT positions and 43 closed out — a net gain of 30 holders — while 136 added to existing stakes and 90 trimmed.
The largest buyer was AQR Capital Management, adding an estimated $135M. The largest seller was Renaissance Technologies, cutting an estimated $31.4M.
- 346 institutional investors held Sarepta Therapeutics (SRPT) as of Q4 2025, up from 320 in Q3 2025.
- Funds reported $2.01B of Sarepta Therapeutics stock for Q4 2025, up 20% quarter-over-quarter.
- 73 funds opened new Sarepta Therapeutics positions in Q4 2025 and 43 closed out, a net change of +30 holders.
- The largest Sarepta Therapeutics buyer in Q4 2025 was AQR Capital Management, an estimated $135M added.
- The largest Sarepta Therapeutics seller in Q4 2025 was Renaissance Technologies, an estimated $31.4M sold.
Based on aggregated 13F filings for Q4 2025.